Aetna, one of the USA's leading diversified health care benefits companies, has entered into a value-based agreement with pharma giant Merck & Co (NYSE: MRK) for the type 2 diabetes drugs Januvia (sitagliptin) and Janumet (sitagliptin plus metformin).
Merck will also become the first health care company to participate in AetnaCare, a new personalized health and wellness care initiative that provides members the knowledge, tools, and support to take a proactive role in managing their own health.
Measuring value differently
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze